Karin Smyth MP: speeches

Speeches

• 26 Jun 2025 · IVF Egg Donation: Young Women · Hansard source

  More

  It is a pleasure to serve under your chairmanship, Mr Efford. I thank the hon. Member for Strangford (Jim Shannon) for securing this debate on egg donation in young women. He raises a number of important points, which the Government take seriously. I absolutely assure him that there are rules and regulations around egg donation in this country. Hon. Members in this debate have talked about the potential concerns of the long-term impact of egg retrieval, and the potential incentive of the compensation offered for egg donation, particularly for young women on low incomes. I hope to address those points in my remarks. For people who are struggling to conceive, which may be for a variety of reasons, receiving donor eggs can be life-changing—as we have heard in this debate—and enable them to start a family of their own. Donating eggs should be a purely altruistic act, and choosing to become a donor is a complex decision. In the UK, the average egg donor is between 31 and 32 years of age. That average has remained stable since records began in 1991. Egg donors are typically UK-based, with around 3% of donor eggs imported from abroad. There were around 3,800 IVF cycles using donor eggs in 2023, which is an increase from around 3,600 in 2019. Those donors support around 2,000 to 3,000 people a year who would otherwise not be able to have a baby. I recognise their generosity, although, as my hon. Friend the Member for Newcastle upon Tyne East and Wallsend (Mary Glindon) said, we also recognise that egg donation procedures come with risks, and they should not be undertaken lightly. The HFEA ensures that licensed fertility clinics are following law and guidance in relation to egg donation. The Government agree with the point made in this debate that young women should be fully informed of any risks when making the decision to donate their eggs, and that clinics must ensure that women are fully informed and supported throughout the egg donation process. It is mandatory for clinics to provide counselling to women before egg donation to ensure that they understand all the potential risks, and legal and social implications, of donation. Donating eggs is generally very safe, and most women do not experience any health problems beyond discomfort during the stimulation of the ovaries and the egg collection procedure. I do not want to minimise that experience of discomfort, but where women wish to donate eggs, the HFEA and the Government are committed to making it as safe and accessible as possible. In the short term, there is a potential risk of having a reaction to the fertility drugs used for the donation procedure. If that happens, the effects are normally mild, and can include headaches, nausea or feeling bloated. Donors are advised to let their clinic know if they experience any of those side effects. In some very rare cases, as we have heard, women develop OHSS. It is a serious and potentially fatal reaction to fertility drugs, which happens about a week after eggs have been collected. Fortunately, it is rare, occurring in less than 0.1% of cycles. Because of the serious nature of OHSS, all severe or critical cases must be reported to the HFEA within 24 hours by the patient’s clinic. They are categorised by the HFEA as grade B incidents. A grade B incident involves serious harm to one person, or moderate harm to many. The HFEA’s latest “State of the fertility sector” report found that fewer OHSS incidents were reported in 2023-24, with 53 severe and critical cases reported by UK clinics. In recent years, there has been widespread interest in donation, and figures show that the number of egg donors is rising. We heard from my hon. Friend the Member for Newcastle upon Tyne East and Wallsend and the Opposition spokesperson, the hon. Member for Sleaford and North Hykeham (Dr Johnson), about the importance of having conversations and asking questions about the long-term impact on women’s health, which is generally an under-researched area. The Government recognise that and would welcome studies in this area. If there is anything I can add to that following this debate, I will follow up with hon. Members on the opportunities for understanding the wider long-term implications for women’s health in this area. At the public board meeting last year, the HFEA discussed the rates of compensation offered to egg and sperm donors. Since 1 October 2024, egg donors have received £985, which is up from £750. That increase in donor compensation was the first since 2011, and reflects the rise in inflation. The compensation offered to them is intended to reflect their time and the nature of the procedure, rather than being an attempt to monetise donation in the UK. I want to address some of the points raised by Members to do with the variability of access to fertility services more broadly. Infertility affects one in six women of reproductive age worldwide. It is a serious condition that impacts wider family, relationships and mental health, as we heard from the Liberal Democrat spokes- person, the hon. Member for Chichester (Jess Brown-Fuller). I congratulate her friends, Lottie and Marvin, on the arrival of their child. This Government expect integrated care boards to commission fertility services in line with the National Institute for Health and Care Excellence guidelines. NICE is currently reviewing the fertility guidelines, and will consider whether the current recommendations for access to NHS-funded treatment are still appropriate. I look forward to the guidelines being published; we will work with integrated care boards to determine how best to improve their local offer and ensure equity of access for affected couples.

• 26 Jun 2025 · IVF Egg Donation: Young Women · Hansard source

  More

  I have addressed the issue of compensation. It rose in response to inflation, for the first time since 2011. We have no further plans to start a study specifically on health. As I said in my remarks to others, we understand that broader outcomes in women’s health is an under-researched area. Bringing forward trials is the usual response. If we need to add anything else to that, I will make sure we do so, but there are no other plans currently. Advertising is governed in this country by the Advertising Standards Authority, which issued a joint enforcement notice in 2021 with the HFEA to ensure that fertility clinics and others were aware of the advertising rules and treating customers fairly. I am afraid I cannot comment on Scotland, where I understand there has been a large advertising campaign. That is not in my ken, although it is covered by the HFEA, which is a UK-wide body, so that is a bit of a complication. If there is anything to report back on with regard to Scotland, without me stepping on devolved issues, I will make sure we do so. I again thank hon. Members for securing the debate and acknowledging the altruism of the women who choose to donate their eggs and help to give others a much longed-for baby. I assure Members that this Government will monitor the issues raised this afternoon. Women’s health and tackling inequalities are central to the priorities that we will take forward in the 10-year plan.

• 24 Jun 2025 · Department of Health and Social Care · Hansard source

  More

  I thank the interim Chair of the Health and Social Care Committee, my hon. Friend the Member for Birmingham Erdington (Paulette Hamilton), for securing this debate, and all colleagues for taking part. I have been asked to condense my comments, so I hope that I can address her questions, but if I do not cover them, we will of course make sure that she has a written response. We are honest about the challenges facing the health service, and we are serious about solving them. That is why we published the independent review led by Lord Darzi, which provided a full and frank assessment of the state in which the nation’s health service was left by the Conservatives after 14 years of government, aided in the first five years by Liberal Democrat colleagues. That investigation highlighted the critical challenges facing the NHS, and we have heard about more of them today. They include a significant increase in people living with multiple long-term conditions, and growing demands for mental health services, particularly among children and young people. That is why we are taking the steps that we are taking. The investment we are already making in 2025-26, the outcome of the recent spending review and the forthcoming 10-year health plan will address these root causes by delivering our plan for change commitments, investing in preventive health care and modernising NHS infrastructure, so that we radically reform the NHS. We will deliver three shifts to ensure that the health service can tackle the problems of today—caused by the Conservatives—and of tomorrow. They are: shifting care from hospitals to community; shifting from analogue to digital; and shifting from sickness to prevention. My hon. Friend the Member for Birmingham Erdington said that there were highly optimistic assumptions in the planning process, and that robust, detailed plans and efficiency savings were needed if we are to deliver on those assumptions. I agree. I am optimistic about our ability to deliver, but I am also realistic and very focused on delivery. Like my hon. Friend the Member for Chelsea and Fulham (Ben Coleman), I am already seeing improvements, as are most Members in their constituencies. May I wish him a happy birthday for July, while we are here? My hon. Friend the Member for Altrincham and Sale West (Mr Rand) rightly said that the Labour Government did this before, and we will do it again. The estimates set the Department of Health and Social Care a resource spending budget of £208.1 billion and a capital DEL—departmental expenditure limit—budget of £13.6 billion, an increase from the 2024-25 supplementary estimates budget of £9.6 billion and £2 billion respectively. On capital, we have, as my hon. Friend the Member for Shipley (Anna Dixon) said, reversed the shocking decision by previous Governments to keep raiding capital budgets in order to keep the revenue going. That is why NHS buildings across our constituencies are in the state that they are in, and why we do not have the infrastructure that we need. I was pleased to visit Airedale hospital recently to see the work being done to repair it. On digital and tech, my hon. Friend the Member for Birmingham Erdington will notice that we have a £10 billion dedicated spend for the issues that she quite rightly raised. The Department covers a wider family of organisations, and I can assure the House that we are focused on all parts of the departmental family to make sure that taxpayers’ money is spent as efficiently and effectively as possible. Everybody here has raised particular issues to do with the NHS, so I will briefly remind Members of the outcome of the spending review that my right hon. Friend the Chancellor recently announced. The spending review includes £29 billion more day-to-day funding in real terms than in 2023-24 and the largest-ever capital health budget; there will be a £2.3 billion real-terms increase in capital spending over the spending review period. That is our commitment to the British public. My hon. Friend the Member for Sunderland Central (Lewis Atkinson), with his great experience of the health service, said that we need to make sure that we have good public administration. The multi-year settlements can help the system to plan much better. This record investment puts the NHS on a sustainable footing to deliver for the British people. We will cut waiting lists so that, by the end of the Parliament, 92% of patients will start consultant-led treatment for non-urgent health conditions within 18 weeks, delivering on the Prime Minister’s plan for change commitment to prioritise people’s health. We will support the shift from analogue to digital with the investment of £10 billion in NHS technology and transformation between 2026-27 and 2028-29—an increase of almost 50% from 2025-26. We will repair the NHS estate, continuing to deliver the 25 hospitals, with £30 billion over the next five years for day-to-day maintenance and critical safety risks, including the eradication of RAAC. None of that happened under the Conservatives. We will enable 2% productivity growth per year, unlocking £17 billion of savings to be reinvested in frontline services. As well as delivery, the British people rightly expect us to ensure value from this huge investment in the health service. The Secretary of State has marked 2025-26 as a financial reset year with the publication of this year’s planning guidance. He has been clear that all systems must live within their means, exhausting all opportunities to improve productivity, tackle waste and take decisions on how to prioritise resources to best meet the health needs of their local population. All systems are now planning to achieve a balanced financial position in 2025-26, recognising that £2.2 billion of deficit support has already been provided. We will therefore close the £4.4 billion initial gap in full. Financial plans support the delivery of key operational performance targets for elective, cancer, and urgent and emergency care at a national level set out in the guidance. We are working closely with NHS England on key aspects of delivering that. I assure the Chair of the Select Committee that I meet colleagues from across the Department of Health and Social Care and NHS England weekly to go through those plans in a robust manner. There is a lot to get through, so I am sorry that we have lost a lot of time to respond to colleagues. We are particularly looking at productivity and efficiency targets. We are ensuring that the financial performance and improvement programme for 2025-26 learns the lessons of the past. We will focus on cost variation and on upskilling finance teams and wider leadership to ensure that there is good governance in our reporting practice. We will issue the NHS performance assessment framework and have a targeted approach to recovery because the current model does not work. We are looking at ICB reform, as has been discussed. We want to ensure there is a reduction in the variation of cost across the system so that we can get more care and support to the frontline. We are focusing much more on medium-term planning to have a long-term financially sustainable system for systems and providers. Thanks to this Government’s record investment, we are taking steps towards fixing the foundations of our NHS to make it fit for the future. We will set out more details on our plans shortly in the forthcoming 10-year plan, which will lead the NHS to meet the challenges set out in the plan for change and build an NHS fit for the future.

• 19 Jun 2025 · Incontinence · Hansard source

  More

  It is a pleasure to see you in the Chair, Mr Deputy Speaker; you have done an excellent job of making sure that all Back Benchers get to contribute to this afternoon’s important debate. I will have to cut some of my comments, but hopefully I will get to address everybody’s points. We are having this debate during World Continence Week, and I congratulate my hon. Friend the Member for Dudley (Sonia Kumar) on securing it. There could not be a more appropriate time to raise awareness of this issue. Millions of men, women, young people and children are living with bowel and bladder problems. Incontinence is an issue that robs people of their dignity, as we heard from my hon. Friends the Members for Chelsea and Fulham (Ben Coleman) and for Harlow (Chris Vince), and too many suffer in silence. As my hon. Friend the Member for Dudley rightly says, this subject is taboo, and I congratulate her on securing her first debate in the Chamber. It is great to have her expertise in this area. All continence problems can be debilitating and life-changing. They affect a wide range of care groups, and can be a particular concern for older people. In recent years, public discussion and awareness has opened up. The advertising of products has become slightly more commonplace, helping people to normalise these issues, with which so many people live from day to day. However, we are still a very long way from being a society that supports people with incontinence to live without stigma. As these issues affect people of all ages, we need to recognise that different approaches are required. We heard an excellent contribution from the hon. Member for Dumfries and Galloway (John Cooper), who raised that point, as did the hon. Member for Farnham and Bordon (Gregory Stafford). The hon. Member for Strangford (Jim Shannon) talked about children, and my hon. Friend the Member for Nuneaton (Jodie Gosling) talked passionately about people with learning disabilities. There is no one-size-fits-all approach to managing incontinence, but dignity and compassion must be at the heart of the care provided. That is why we are introducing reforms to put the patient at the heart of the care pathway and the decision-making process around it. The 10-year health plan, and its focus on the three shifts needed to deliver a modern NHS—moving from hospital to community, from analogue to digital, and from sickness to prevention—will benefit people at risk of developing incontinence and those already living with it. For example, preventing type 2 diabetes or helping people into remission will help to reduce the number of people who develop continence problems as they go through life. We have heard many contributions about women’s health. NHS England has established a perinatal pelvic health service, which focuses on the prevention, identification and timely treatment of a range of issues antenatally and for at least 12 months after birth. The initiative aims to support women who experienced trauma during childbirth, including conditions such as urinary incontinence and pelvic organ prolapse, as noted by my hon. Friend the Member for Gravesham (Dr Sullivan). In addition to perinatal pelvic health services, continence services are provided more widely via women’s health hubs, and the core specification outlines that incontinence care is a key consideration for local organisations when establishing hubs. I commend my hon. Friend the Member for Wolverhampton West (Warinder Juss) for bringing his expertise and experience to this debate, and for supporting so many women. I know that in the last Parliament many Members of this House supported women through the horrors of mesh implants, and we are moving that issue forward. By moving from sickness to prevention, the Government want to shorten the amount of time people spend in ill health and to prevent illnesses before they happen. Although prevention is extremely important, we must also ensure that those living with incontinence receive the best possible care, wherever they live. A key part of that involves the NHS providing high-quality guidance on how to care for people living with incontinence. The National Institute for Health and Care Excellence has published five guidelines on the management of urinary and faecal incontinence, which cover the management of urinary incontinence in people with neurological disease, the prevention and management of pelvic floor dysfunction, and pelvic organ prolapse in women. NICE has also published advice on a further 14 products for urinary incontinence, and on 12 products for faecal incontinence. My Department has commissioned NICE to produce late-stage assessment guidance on one-piece closed bags for colostomies, and on intermittent urethral catheters for chronic incomplete bladder emptying in adults. These late-stage assessments will gather the views of clinical experts and patients to help NICE assess and compare the value of products in widespread use across the NHS. In addition to NICE’s guidance, the NHS must have regard to the “Excellence in Continence Care” guidance, published in 2018. NHS England has also produced guidance on safer bowel care for patients at risk of autonomic dysreflexia, a serious medical condition that can affect people with spinal cord injuries. The guidance offers resources to support safer bowel care practice, and highlights the importance of implementing the excellent incontinence framework. In addition, the Nursing and Midwifery Council has professional standards relating to bladder and bowel nursing care. Its code places a strong emphasis on the principle of prioritising people, setting out the expectation that registrants should always respond to individual patient needs. NHS England is also developing a best practice catheter care pathway across all settings, which is to be completed by the end of this year. The provision of suitable care, with the products necessary to deliver that care, is essential for minimising the physical harm related to complications and treatments for continence problems, which can lead to admission to hospital for extended lengths of stay. The NHS will commission pathways of care that ensure early assessment and effective management of incontinence, along with other bladder and bowel problems. These pathways will take account of the impact of urinary tract infections on social, physical and mental wellbeing to reduce expensive pad usage, high-cost complications, and unnecessary hospital and care home admissions. As we have heard, our focus on the shift from hospital to community will drive more joint working in neighbourhoods between primary care, pharmacies, community healthcare and social care to help people manage incontinence at home. This will help them to access the right self-care and the right professional support so they are not passed from service provider to service provider. It will also reduce their need for emergency hospital admissions, as we heard from my hon. Friend the Member for Nuneaton. My hon. Friend the Member for Penrith and Solway (Markus Campbell-Savours) made some excellent points about access to facilities, and I know he will keep pressing my hon. Friends in the Ministry of Housing, Communities and Local Government about that issue. His points were echoed by my hon. Friend the Member for Colchester (Pam Cox). As I stated at the outset, shifting care into community settings is one of our three shifts, and we will shortly be publishing the 10-year plan. Once again, I thank my hon. Friend the Member for Dudley for bringing forward this debate to raise awareness of this important but often overlooked issue.

• 17 Jun 2025 · Topical Questions · Hansard source

  More

  I thank my hon. Friend for that important question. The Government are carefully considering the work of the patient safety commissioner and her report, which sets out the options for redress. This is a complex issue involving input from different Government Departments. We will provide a further update on the commissioner’s report soon.

• 17 Jun 2025 · Topical Questions · Hansard source

  More

  Such contraceptives are an emerging technology that will be subject to clinical and other relevant assessment before being considered for use in England. The Government remain committed to ensuring that women can access their preferred method in a timely manner. A range of contraception is available free of charge from a range of settings. That includes a copper coil, which is a non-hormonal, non-steroidal contraceptive device.

• 17 Jun 2025 · Topical Questions · Hansard source

  More

  My hon. Friend raises an important question. We are committed to improving women’s experience of gynaecological procedures, including hysteroscopies. Women should be provided with information prior to their procedure so that they can make an informed decision about the procedure and pain relief options, including local or general anaesthetic. He will probably make further representations, which we will certainly look at.

• 17 Jun 2025 · Topical Questions · Hansard source

  More

  In the light of the broader pressures and changes in the NHS, we have been considering the ambitions on fertility services and fairness for all couples. The National Institute for Health and Care Excellence is reviewing its fertility guidelines, which will be the clinical standard for the future. I know that my hon. Friend will ensure that she and the group she talks about keep an eye on that, and that she will work with them. I am happy to keep working with her on how we best support ICBs to improve their local offer.

• 17 Jun 2025 · Medicine Supply Chain: Community Pharmacies · Hansard source

  More

  Increasing the resilience of the UK medical supply chain is a key priority. I regularly meet the team to routinely take action to mitigate supply issues, including requesting additional stock, identifying alternative global sources and issuing management advice. Although the Department has no plans to conduct a specific review, we constantly work to identify and take forward further actions to reduce the impact of medicine shortages, including targeted winter monitoring.

• 17 Jun 2025 · Medicine Supply Chain: Community Pharmacies · Hansard source

  More

  I congratulate my hon. Friend and constituency neighbour on his dedicated career in community pharmacy, and thank him for the expertise that he brings to the work of the all-party parliamentary group to help Members understand the impact of this issue on patients and pharmacies. I am planning to hold a parliamentary event on the subject in the autumn, and I am keen to work with the APPG to make it a success for all Members.

• 17 Jun 2025 · Medicine Supply Chain: Community Pharmacies · Hansard source

  More

  The hon. Lady has asked an important question about the pharmaceutical industry, which is key to the country’s growth mission and to supporting all our constituents and the entire country. As we know, my right hon. Friend the Prime Minister is currently attending the G7 summit. We have good relationships with America, and the Department is working closely across Government to ensure that the same stability of supply remains for our constituents.

• 17 Jun 2025 · Medicine Supply Chain: Community Pharmacies · Hansard source

  More

  The long-term viability of pharmacies and, indeed, the whole NHS was under threat from the right hon. Gentleman and his party, but thanks to this Government, it is being made fit for the future. This is a serious issue for all our constituents, and we want to make the system work better. The right hon. Gentleman will see from the 10-year plan that we will make the NHS fit for his constituents, mine and those of every other Member.

• 17 Jun 2025 · Cancer Diagnoses · Hansard source

  More

  I am delighted that my hon. Friend’s constituents will benefit from the £70 million investment. These machines are game changing and will reduce the number of visits for his constituents. They are also more reliable, which gives more capacity to the system. That is better for staff, as there will be less appointment cancellations. That is exactly the sort of thing we want to see more of, and we are delivering that under this Government. It is the result of our drive to reduce long waits and treat more people quicker. That was reinforced in last week’s spending review, and it is exactly what his constituents deserve.

• 17 Jun 2025 · Cancer Diagnoses · Hansard source

  More

  Reducing waiting times for cancer diagnosis remains a key priority. Under this Government, an extra 99,000 patients have had cancer diagnosed or ruled out. This has been supported by investment, including in Cancer 360—a digital innovation that brings patient data into one central platform—and in NHS England’s cancer innovation open call to fast-track cutting-edge interventions into practice. Our forthcoming national cancer plan will set out how we will speed up cancer diagnosis even further.

• 17 Jun 2025 · Cancer Diagnoses · Hansard source

  More

  Many hon. Members across the House rightly highlight the actual experience of people throughout the entire pathway. We have heard about the investment we are making in machines and in staff to ensure, on exactly this point, that people get not just that faster diagnosis—that is so important, particularly if cancer is ruled out—but faster care across the entire pathway. The majority of people on waiting lists are on them for diagnostics, which is exactly why we are investing more in capital and investing in staff to ensure that the process is quicker and better for patients. If the hon. Member wants to write to me about any particular issues, I will obviously respond to her.

• 17 Jun 2025 · Cancer Diagnoses · Hansard source

  More

  The work that the hon. Member is doing locally with that group is essential. I will ensure that we have a good response for him, whether it is meeting me or a colleague.

• 17 Jun 2025 · Cancer Diagnoses · Hansard source

  More

  My hon. Friend is right to highlight that issue. I commend her great work not just on the APPG but on leading the Health and Social Care Committee on behalf of its Chair, the hon. Member for Oxford West and Abingdon (Layla Moran). She is right to highlight that it is a priority for the Government to diagnose cancers earlier and improve survival rates. That is particularly important for the group of people with rare cancers. The APPG’s report will inform the development of our national cancer plan, which will seek to include all aspects of care throughout the entirety of the cancer pathway.

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  We talk regularly with our colleagues in Northern Ireland, and I am always happy to do so. As the hon. Lady knows, this matter is devolved, so it is a matter for Northern Ireland, and we respect the devolution settlement. Our elective reform plan, published in January 2025, builds on the investments already made with an ambitious vision for the future of diagnostic testing. This will include more straight-to-test pathways, increasing and expanding community diagnostic centres, and better use of technology. With nearly 170 community diagnostic centres up and running, they can take on more of the growing diagnostic demand in elective and cancer care. We will also deliver additional capacity in 2025-26 by expanding some existing centres and building up to five new ones. We will address the challenges in diagnostic waiting times, providing the CT, MRI and other tests that are needed to reduce the elective and cancer waits. Members know that the National Institute for Health and Care Excellence—we have heard a little about it this evening—is an independent body responsible for assessing whether new licensed medicines can be recommended for routine use in England, based on a thorough assessment of their clinical and cost effectiveness. The NHS is legally required to fund NICE recommended medicines, ensuring consistency of access for NHS patients wherever they live in England. NICE is able to recommend promising new cancer medicines for use through the cancer drugs funds, which supports patient access while real-world evidence is generated to address clinical uncertainties. Through the cancer drugs fund, NHS patients also benefit from access to cancer medicines from the point of positive draft NICE guidance, accelerating access to clinically and cost effective medicines by up to five months. Through this process, many thousands of patients, including patients with prostate cancer, have been able to benefit from effective new treatments at prices that represent value to the NHS. The drug that is the subject of this debate, abiraterone, is licensed, as my hon. Friend the Member for Ealing Central and Acton said. It is recommended by NICE for use in the treatment of certain types of metastatic prostate cancer, and it is now routinely available to NHS patients in England in line with the NICE recommendation. NHS England has recently put in place an interim commissioning policy that makes abiraterone available for men with high-risk, hormone-sensitive metastatic prostate cancer, pending the outcome of NICE’s update of its negative guidance. I am pleased that this approach was agreed between NICE and NHS England late last year to ensure uninterrupted access to abiraterone for men leaving the STAMPEDE trial. My hon. Friend raised particular concerns about access to this drug for men with non-metastatic prostate cancer. First, it is important to note that abiraterone is not licensed by the MHRA for use in this indication, and it is therefore off-label. NICE does not evaluate the off-label uses of medicines, and the drug is also now off-patent and available generically, which means there is no single manufacturer that could sponsor an MHRA licence application or NICE evaluation. It is therefore for NHS organisations to take decisions on funding based on the available evidence. NHS England considered abiraterone for the treatment of non-metastatic prostate cancer through its clinical prioritisation process last year. Through this process, NHS England concluded that evidence supported the routine commissioning of the drug in this indication. Approximately 7,000 men per year could be eligible for this drug, and it is estimated that it would cost an additional £20 million per year to fund that. While, as my hon. Friend said, there may be some cost savings in the pathway from preventing the disease’s progression, these are unlikely to materialise for about five years and would not impact the up-front costs of the £20 million per year for the additional out-patient monitoring and drug cost. I had not heard the figures she outlined, but I will get back to her on some of the questions she asked, and it would be helpful to know where those figures are from. Unfortunately, it has not been possible to identify the necessary current funding to support the commissioning of abiraterone for this purpose or any other treatments in this prioritisation round. I know that is disappointing for those affected, and I want to acknowledge that this is a really difficult and unusual situation. However, I want to assure my hon. Friend and other hon. Members that the funding position for this treatment does not mean that there are no treatment options. The NICE guideline on prostate cancer recommends the treatment of non-metastatic prostate cancer with surgery and radiotherapy. I want to assure hon. Members that NHS England is keeping this position under review, and would reconsider funding for abiraterone for non-metastatic prostate cancer if the funding position changes. Earlier this month, NHS England met Prostate Cancer UK, which shared its financial model of the expected cost impacts. NHS England is reviewing this in more detail, and I encourage it to continue those discussions. In closing, I recognise how hard it is when patients want access to effective treatments. I also recognise the distress and worry it causes not only for patients, but for their families and friends. The Government are committed to ensuring that we provide access to the most innovative and effective medicines, but it has to be in a way that is sustainable and affordable for the NHS. It is right that NHS England continues to engage with Prostate Cancer UK, and I know that my hon. Friend and other Members will keep an eye on this and similar issues with drugs coming forward. The national cancer plan will seek to improve every aspect of cancer care, to better the experience and outcomes of people with cancer. Our goal is to reduce the number of lives lost to cancer over the next 10 years. I am grateful for the opportunity to respond to the debate this evening. Question put and agreed to.

• 17 Jun 2025 · Prostate Cancer Treatment · Hansard source

  More

  I thank my hon. Friend the Member for Ealing Central and Acton (Dr Huq) for securing the debate, and I thank the other Members who have spoken. As my hon. Friend has said, more than 50,000 men are diagnosed with prostate cancer every year, and one in eight will be diagnosed with it during their lifetime. I commend her for raising an issue that I know is very personal to her, as she has articulated so well. I am sure that her late father is watching her carefully. She was also right to support her constituent Peter by raising this issue, which affects so many men, and to highlight the number of black and minority ethnic men presenting with the disease. That is something on which we have all campaigned very strongly. Timely and equitable diagnosis and access to innovative medicines for the treatment of prostate cancer are of the utmost importance. To support faster diagnosis, NHS England has redesigned pathways to maximise capacity. We are also aware of very early-stage trials of the use of artificial intelligence in prostate cancer detection, and we look forward to a formal report on those trials, so that the evidence can be considered carefully.

• 17 Jun 2025 · Biopsy Waiting Times · Hansard source

  More

  More patients are now getting world-leading testing technology in the NHS as part of our mission to revolutionise cancer care in this country. The Government are spending £600 million a year in capital on diagnostics, including for the first time funding for the automation of histopathology laboratories to improve productivity. We are also funding pathology networks to reach digital maturity by 2026, which will reduce unnecessary waits and repeated tests.

• 17 Jun 2025 · Biopsy Waiting Times · Hansard source

  More

  The hon. Member raises an awful case on behalf of his constituent. Of course, our targeting of waiting lists includes diagnostics. What happened in that case should not happen anywhere, and I will ensure that he gets a response as soon as possible.

• 17 Jun 2025 · Under-18s Sunbed Ban · Hansard source

  More

  As someone who was diagnosed myself with an earlier stage melanoma, I really commend the work of my hon. Friend’s constituent. I never used sunbeds and I spent holidays in my youth in Ireland, so I never saw much sun either—sorry to the Irish tourism board. As my hon. Friend says, it is an overwhelmingly preventable cancer, including by using sunscreen, better clothing, shading and no sunbeds. It is up to event organisers to provide sunscreen at events, but my hon. Friend is right. I want to personally thank Melanoma Focus for the support it gave me during my diagnosis. There are great charities out there to support people. I am sure a Minister will be in contact with my hon. Friend and her constituent soon to highlight the prevention aspects of this disease.

• 17 Jun 2025 · Under-18s Sunbed Ban · Hansard source

  More

  The Sunbeds (Regulation) Act 2010 banned the use of commercial sunbeds for under-18s, requiring businesses to prevent under-age use. The Department has commissioned the Committee on Medical Aspects of Radiation in the Environment to review the Act, including the effectiveness of the under-18 ban.

• 12 Jun 2025 · Spending Review: Health and Social Care · Hansard source

  More

  The hon. Gentleman makes an excellent point on primary care, which sees 90% of contacts with the NHS and is where most people experience the NHS. That is why it is very much in our sights to support that work. As part of our 10-year plan, we will bring forward the neighbourhood health service to make sure that people can be seen more locally. That will be built around using primary and community care to best effect. He makes a point about funding formulas. We had a long debate about that yesterday in Westminster Hall, and it is an area of huge controversy. He will see over the coming weeks how the funding is allocated. NHS England did issue—if he has not seen it, I will make sure that he has access to it—guidance on the funding formula and where the different systems are in relation to that. We want to move everybody towards that target, and I am happy to discuss that with him once he has had a look.

• 12 Jun 2025 · Spending Review: Health and Social Care · Hansard source

  More

  With permission, I would like to make a statement on the outcome of the spending review for the Department of Health and Social Care. This Government were elected on a manifesto to fix our broken NHS and make it fit for the future. Our job is twofold: first, to get the NHS back on its feet and treating patients on time again; and secondly, to reform the service for the long-term so that it is fit for the future. That is why, in her autumn Budget, my right hon. Friend the Chancellor took the necessary decisions to give health and social care a record uplift in day-to-day spending at the conclusion of the first phase of the spending review. The Department for Health and Social Care received a cash injection of £26 billion covering day-to-day spending and capital investment in 2025-26, compared with the 2023-24 out-turn. All Opposition parties have rejected that investment and those changes to repair the damage done to our NHS and move it forward. They have rejected two above-inflation pay increases for our NHS staff, the recruitment of 1,700 more GPs and the agreement of a GP contract for the first time since the pandemic, the biggest investment for hospices in a generation, the biggest expansion of carer’s allowance since the 1970s, a boost for older and disabled people through the disabled facilities grant, and the biggest real-terms increase to the public health grant in nearly a decade. We have also given pharmacies the biggest funding uplift in years, ensured that women across the country can access the morning after pill free of charge, frozen prescription charges for the first time in three years, enabled an extra 3.5 million appointments for operations, consultations, diagnostic tests and treatments—reaching and surpassing our manifesto pledge seven months early. I can update the House on waiting lists, which, as of this morning, have fallen by over 30,000 compared with last month, amid a reduction of 232,000 since this Government took office. I could go on, but I have only 10 minutes, Madam Deputy Speaker, and I would not like to try your patience, so I will make this point briefly. To govern is to choose, and anyone who opposed the decisions that the Chancellor took in her Budget must tell us what they would have subtracted from that list. We cannot spend money if we do not raise it. As the Minister of State for Secondary Care, I regularly hear appalling anecdotes from colleagues across the House whose local hospitals, GP surgeries and community services are crumbling, with rusty equipment, leaky pipes and buckets catching rainwater. Phase 1 of the spending review has allowed us to arrest 14 years of shocking neglect and undercapitalisation in the NHS, with a record capital investment of £13.6 billion in 2025-26. [ Interruption. ] The Conservatives do not like it, but I will go on. That money has gone towards repairing our crumbling hospitals, supporting over 1,000 GP surgeries to modernise their buildings, and installing state-of-the-art scanners across the NHS estate, including the latest linear accelerator machines. However, as my right hon. Friend the Secretary of State has made clear, investment must come with reform. This year we have unveiled our plan for change, our elective reform plan, our urgent and emergency care plan and a crackdown on agency spend in order to reinvest £1 billion into the frontline. Yesterday, my right hon. Friend the Chancellor set out the conclusion of phase 2 of the spending review, setting budgets that will enable us to make firm plans to deliver on the people’s priorities in the coming years, while going further and faster on reform. Our settlement increases day-to-day spending on health, bringing the budget for my Department and our NHS up to £232 billion by 2028-2029. That means £29 billion more day-to-day funding for the NHS in England, in real terms, than in 2023-24. We have also secured the largest-ever health capital budget, with a £2.3 billion real-terms increase in capital spending by 2029-30, compared with 2023-24, representing a more than 20% real-terms increase by the end of the spending review period. Let me hammer this point home: investment must be matched by reform. This will be a critical year for the NHS as we achieve better value for taxpayers, who must see their money being spent well and delivering results. We would rather take those difficult decisions now, to save our NHS so that it is there for future generations. NHS England is a top-down organisation—the biggest quango in the world—with a less efficient system than the previous Government inherited in 2010 and twice the headcount at the centre. That is why my right hon. and learned Friend the Prime Minister announced in March that we will bring together NHS England and the Department of Health and Social Care to form a new joint centre. That will put an end to duplication and enable substantial efficiency savings, while bringing the management of our NHS back under democratic control. We will also unlock £17 billion of savings over the spending review period through 2% annual productivity growth in the NHS—money that will be either reinvested in the frontline or used to support radical transformation to make the health system more agile and efficient. Our elective reform plan set out how we will ensure that by the end of this Parliament 92% of patients will not have to wait more than 18 weeks for elective care. This settlement will drive us further towards that goal, with over £6 billion of additional capital investment over five years across new diagnostic, elective and emergency and urgent care capacity, which could deliver more than 4 million additional tests and procedures. We will build on the record capital investment from phase 1 to repair the NHS estate. That means continuing the delivery of 25 new hospitals; investing £30 billion in maintenance and repairs, with £5 billion of it to address the most critical building repairs; and reducing by half the number of hospitals containing RAAC—reinforced autoclaved aerated concrete—over this Parliament. This spending review provides for an increase of over £4 billion for adult social care in 2028-29 compared with 2025-26, including an increase in the NHS contribution via the better care fund. Local authorities with responsibility for adult social care will also benefit from wider reforms to better align funding with need, multi-year settlements and simplification of the funding landscape that enables them to plan more effectively. Last but not least, we have taken steps to simplify targets and better monitor delivery, and we will continue to work with local systems to improve financial and operational performance, to get the most from every penny. A key part of our 10-year plan is driving progress on the three shifts: from analogue to digital, hospital to community and treatment to prevention. On digital, we will invest up to £10 billion in technology and transformation, to start making the NHS app a digital front door and deliver a single patient record. We will work in partnership with the Wellcome Trust to launch the world’s first health data research service, backed by £600 million, to accelerate the discovery of lifesaving drugs. On primary and community care, we will invest in training thousands more GPs, helping to bring back the family doctor through millions of extra appointments a year; in 700,000 additional dentist appointments annually; in at least 8,500 extra mental health staff by the end of this Parliament; and in mental health support teams for every school within five years. Finally, on prevention, our world-leading immunisation programmes will be supported by £2 billion, and we will invest £80 million in tobacco cessation programmes and our Tobacco and Vapes Bill. I want to end by thanking the Chancellor for her unwavering commitment to getting our NHS back on its feet. Fixing broken Britain will not be easy, but nothing that is worth doing ever is. Today I have set out how every penny from the public purse will be matched by reform, to make our NHS fit for the future. We remember we were elected on a manifesto to end sticking-plaster politics and do the hard yards of fixing our country, and we will never betray that promise to the British people. The public have a right to know how public money will be spent, and this is something we take extremely seriously. They can put their trust in this Government, because we have fixed the NHS before, and with the help of this Chancellor, we will fix it again. I commend this statement to the House.